Many studies have demonstrated the importance of the gut microbiome in 25 healthy and disease states. However, establishing the causality of host-26 Importance 47 Study of host-microbiome interactions in humans is largely limited to identifying 48 associations between microbial communities and host phenotypes. While these 49 studies have generated important insight on the link between the microbiome and 50 human disease, assessing cause and effect relationships has been challenging. 51 Although this relationship can be studied in germ-free mice, this system is costly, 52 and it is difficult to accurately account for the effect of host genotypic variation 53 and environmental effects seen in humans. Here, we have developed a novel 54 approach to directly investigate the transcriptional changes induced by live 55 microbial communities on human colonic epithelial cells and how these changes 56 are modulated by host genotype. This method is easily scalable to large numbers 57 of host genetic backgrounds and diverse microbiomes, and can be utilized to 58 elucidate the mechanism of host-microbiome interactions. 59 60 563 1. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. 2012. 564 Diversity, stability and resilience of the human gut microbiota. Nature 565 489:220-230.
microbiome interactions in humans is still challenging. Here, we describe a novel 27 experimental system to define the transcriptional response induced by the 28 microbiome in human cells and to shed light on the molecular mechanisms 29 underlying host-gut microbiome interactions. In primary human colonic epithelial 30 cells, we identified over 6,000 genes that change expression at various time 31 points following co-culturing with the gut microbiome of a healthy individual. The 32 differentially expressed genes are enriched for genes associated with several 33 microbiome-related diseases, such as obesity and colorectal cancer. In addition, 34 our experimental system allowed us to identify 87 host SNPs that show allele- 35 specific expression in 69 genes. Furthermore, for 12 SNPs in 12 different genes, 36 allele-specific expression is conditional on the exposure to the microbiome. Of 37 these 12 genes, eight have been associated with diseases linked to the gut 38 microbiome, specifically colorectal cancer, obesity and type 2 diabetes. Our 39 study demonstrates a scalable approach to study host-gut microbiome 40 interactions and can be used to identify putative mechanisms for the interplay 41 between host genetics and microbiome in health and disease. bacteroidetes and firmicutes (1). In obese individuals, the ratio of these two phyla 68 is altered (6-8). Turnbaugh et al. showed that transplanting the fecal microbiome 69 of an obese mouse to a germ-free mouse causes greater weight gain in the 70 recipient as compared to recipients that received the microbiome of lean mice 71 (9). Goodrich et al. showed that this relationship exists even when the 72 microbiome from obese humans is transplanted into mice (10). The microbiome 73 has also been linked to colorectal cancer (11, 12) and to diseases not directly 74 related to the gut, such as arthritis, Parkinson's disease, and other types of 75 cancer (13) (14) (15) (16) . 76 77 While there are many species that are common among humans, studies have 78 shown that microbiome composition can vary widely across individuals (17, 18) . 79 These differences have been correlated to several factors, such as 80 breastfeeding, sex, and diet (19) (20) (21) (22) (23) (24) . In addition to environmental factors, recent 81 studies also support a key role for host genetics in shaping the gut microbiome. 82 Indeed, microbiome composition is more similar in related individuals than in 83 unrelated individuals (10, 25-28). One caveat of these studies is that, especially 84 in humans, related individuals often share environments and follow similar eating 85 habits, which have a strong effect on the microbiome. In an effort to control for 86 this factor, other studies have attempted to estimate the role of host genetics on 87 the microbiome in mice, where the environment can be regulated, or in groups of 88 people that all share the same environment regardless of relatedness (29) (30) (31) (32) . 89 90 To further examine the effect of host genetic variation on gut microbiome, some 91 groups have performed association studies between host genotypes and 92 microbiome composition (32-35). For example, Blekhman et al. studied 93 93 individuals and identified loci that are associated with microbiome composition in 94 15 body sites that were sequenced as part of the Human Microbiome Project (18, 95 33). Among SNPs associated with microbiome composition, they found an 96 enrichment in SNPs that were identified as expression QTLs (eQTLs) across 97 multiple tissues in the Genotype-Tissue Expression (GTEx) project (36). 98 Additionally, microbiome composition has been found to be tissue-specific and 99 therefore, likely influenced by host gene expression pattern in the specific tissue 100 that interacts with the microbiome. Together, these results suggest that host 101 genetic variants affects microbiome composition through influencing host gene 102 and protein expression. However, we know little about the interplay between 103 human genetic variation, gene expression, and variation in microbiome 104 composition, and the effect of these factors on susceptibility to complex disease. 105 
106
Molecular studies of genetic effects on cellular phenotypes (eQTL, dsQTL and 107 transcription factors binding QTL mapping studies) have been successful in 108 elucidating the link between genetic variation and gene regulation, and have 109 identified hundreds of variants associated with gene expression and transcription 110 factor binding changes (37-42). Here, we present a novel approach to study the 111 interaction between the microbiome, human genetic variation and gene 112 expression in a dynamic and scalable system. We co-cultured primary, human 113 colonocytes (epithelial cells of the colon) with the gut microbiome of a healthy 114 individual (extracted from a fecal sample) to study host cell gene expression 115 6 response to microbiome exposure. We identified over 6,000 genes that 116 significantly change their expression in the host following microbiome exposure. 117 These genes are enriched for GWAS signals, suggesting that regulation of their 118 expression is a potential mechanism for the associations found between host 119 disease status and microbiome composition. In addition, to learn about host 120 genetic variants that play a role in host-microbiome interaction, we studied allele-121 specific expression (ASE) and identified 12 genes that demonstrate an 122 interaction between genotype and microbiome exposure. Future studies can use 123 this approach to characterize host response to the microbiome and determine the 124 causal relationship in the context of specific diseases and traits. Table   134 S1). We analyzed the DNA of the fecal extract through 16S sequencing followed 135 by data processing using QIIME (12, 43, 44) to quantify microbial species 136 present. This fecal extract showed a normal composition of bacteria phyla with 137 Firmicutes and Bacteroidetes representing the most abundant taxa, consistent 138 with previous studies of gut microbiota composition in healthy individuals (Table   139 S1) (18). 140 141
We exposed the colonocytes to two different densities of live microbiome 142 extract (as measured by OD600), including 10:1 and 100:1 bacteria:colonocyte 143 ratios, termed High and Low concentration, respectively. We cultured the 144 colonocytes in low Oxygen (5% O 2 ) to recapitulate the gut environment for 4 and 145 6 hours under three conditions: with high and low concentrations of bacteria and 146 alone, as controls ( Figure 1B) . This resulted in 5 experimental conditions: Low-4, 147 Low-6, High-4, CO4 and CO6. Experimental replicates were collected for each 148 condition: two replicates for Low-4 and High-4 and three replicates for Low-6, 149 CO4 and CO6. We collected and sequenced the RNA in order to learn about the 150 host cell response through study of gene expression and to identify genes with 151 allele-specific expression induced by the microbiome.
153
Transcriptional changes induced by the gut microbiome 154 First, we searched for genes that were differentially expressed (DE) in the 155 colonocytes following exposure to the gut microbiome. We used DESeq2 (45) as 156 described in the methods to characterize differential gene expression in the 157 treatment samples, across biological replicates. We focused on genes with 158 significant differences using a Benjamini-Hochberg adjusted p-value < 0.1 and 159 |log 2 (Fold-Change)| > 0.25. With this method we identified 3,320 genes that 160 change expression in Low-4 relative to CO4 (55% up-regulated), 1,790 genes in 161 Low-6 relative to CO6 (57% up-regulated) and 5,182 genes in High-4 relative to 162 CO4 (49% up-regulated) resulting in 6,684 genes that had at least one transcript 163 that was differentially expressed (DE) under any of the three conditions ( Figure   164 2, Figure S1 , and We next examined the function of the genes that change their expression in the 183 host. We identified genes involved in pathways previously shown to be affected culturing we find immune system process. We wondered whether immune 203 response activation is stronger under certain conditions. Specifically, we tested 204 whether the high dose of microbiome at 4 hours had a stronger effect on the 205 immune response than the low dose at 4 hours. We identified 2,094 genes that 206 were differentially expressed between High-4 and Low-4, with transcripts from 207 1,308 genes showing increased expression at the higher concentration and 208 transcripts from 788 genes showing decreased expression at the higher 209 concentration of microbiome (Table S3 ). When we searched among the genes 210 that are increased in expression with the higher concentration of microbiome, we 211 found several immune-related GO categories ( Figure S2 ). These data suggest 212 that a higher microbiome concentration elicits a stronger immune response in 213 host cells. First, we hypothesized that if we identify a differentially expressed gene in our 228 data that is also associated with a disease, it is likely that changes in the 229 microbiome influence the gene's expression, thereby contributing to the health of 230 the host. To test this hypothesis, we studied genes that were previously reported 231 to be associated with any complex trait (NHGRI GWAS database) (62), as 232 defined in the Methods. We searched among genes that were differentially 233 expressed, in the same direction, in all 3 treatments and found enrichment for 234 genes associated with complex traits (Fisher's Exact test p-value < 10 -10 , OR = 235 1.8). We then focused on several diseases that have already been linked to 236 microbiome composition. We found that DE genes were enriched for genes (Table S4 ). Additionally, we found that the enrichment of genes 243 associated with colorectal cancer is significant also when we used a 244 complementary approach that accounts for the differences in the distribution of p-245 values across GWAS ( Figure 3C ). For this analysis, we used a range of -log 10 (p-246 value) cut-offs for each disease in the GWAS catalog, and identified the overlap 247 between the genes significantly associated with the disease at each cutoff and 248 DE genes in the current study. Using this approach, we also found enrichment 249 among several autoimmune diseases that have been previously linked to 250 variation in the microbiome, such as atopic dermatitis, celiac disease, and 251 inflammatory bowel disease (63-65). These results support our system as a 252 useful method for studying genes and interactions involved in organismal traits. 253 Moreover, dysregulation of the genes that are both differentially expressed and 254 associated with these diseases may represent a mechanism that causes the 255 pathological state through host cell response to the gut microbiome. Future 256 studies utilizing microbiomes from healthy and diseased individuals will be able 257 to further shed light on how different microbes may influence disease risk through 258 changes in host gene expression.
260
Allele-specific expression 261 Genetic variants associated with microbiome composition have previously been 262 linked to expression changes in humans through eQTL studies (33). However, to 263 date, there are no reports in humans on the effects of genetic variants on the 264 host transcriptional response to the microbiome. In order to identify genetic loci 265 that may influence host gut-microbiome interactions through their influence on 266 gene expression, we studied allele-specific expression (ASE) (37-42). This 267 analysis is ideal for our study (using colonocytes from a single individual) as it 268 uses the genotypes and allelic imbalance for each individual separately to assess 269 genetic control, as opposed to using multiple individuals to determine a 270 correlation in a population between genotypes and expression (37-42). The 271 caveat is that we can only assess SNPs that are heterozygous in our sample and 272 deeply covered by sequencing reads. To characterize ASE in our samples, we 273 utilized QuASAR (66), a method to detect heterozygous sites in a sample and 274 utilize these sites to identify ASE. We found an average of 5,984 heterozygous We then formally tested whether host transcriptional response may be 288 modulated by an interaction between host genetics and the microbiome. 289 Previous studies have examined gene-by-environment interaction in response to 290 infection by searching for response expression quantitative trait loci (reQTLs), 291 where the genetic effect on gene expression is only present under certain 292 conditions (67-70). However, this type of study requires many individuals to gain 293 enough statistical power. Instead, we searched for gene-by-environment 294 interactions by examining ASE conditional on the exposure to the microbiome 295 (conditional ASE, cASE). We identified 12 SNPs in 12 different genes that show 296 cASE under any of the three treatment conditions (empirical FDR < 12%) ( Figure   297 5A-B, Table S7 and Figure S3 ). These genes represent host response that is 298 regulated by both host genetics and the interaction with the gut microbiome. 299 Two of the 12 genes with cASE have been implicated in the immune response 300 (USP36, PIP5K1A), while 8 of them have been linked to a disease affected by 301 dysbiosis in the gut (AFAP1L2, PIP5K1A, GIPC1, ASAP2, USP36, RNF213, 302 KCTD12, LASP1) (71-81). For example, we find cASE at SNP rs1130638 in 303 LASP1 as well as increased total expression of LASP1 following exposure to the 304 high concentration of microbiome at 4 hours (Figure 5A and 5C) . This suggests 305 that the gut microbiome has a stronger effect on LASP1 upregulation in the 306 presence of a specific allelic variant. LASP1 encodes a protein that binds to actin 307 and regulates the cytoskeleton, and it has previously been shown to increase in 308 expression following infection. Specifically, infection with hepatitis B virus X 309 increased LASP1 expression and led to cell migration (82). However, when 310 LASP1 expression was knocked-down following exposure to the virus, 311 subsequent cell migration and movement was also reduced. Furthermore, 312 colorectal cancer cells also show higher expression of LASP1, suggesting that 313 LASP1 plays a similar role in colonocytes. Together, these data suggest another 314 mechanism by which exposure to the microbiome may lead to cell migration and 315 perhaps carcinogenesis through influencing ASE and genotype-dependent 316 expression of LASP1. The gut microbiome has been shown to be complex and variable under 320 physiological and pathological conditions. While studies of the microbiome have 321 become more common, in humans, they have been mostly limited to identifying 322 associations between microbial communities and host phenotypes. Here, we 323 have developed a novel approach to directly investigate the transcriptional 324 changes induced by live microbial communities on host colonic epithelial cells 325 and how these changes are modulated by host genotype. The advantage of this 326 method as compared to in vivo studies in mice is that it allows for high- 327 throughput testing of multiple microbiome and host combinations with quick 328 assessment of the interaction. Previous studies examining the host-microbiome 329 interaction have studied germ-free mice exposed to the gut microbiome of 330 humans (10, 46). While these studies have generated important insight on host-331 microbiome interactions, they have distinct caveats and limitations. First, while 332 the environment of mice can be well-controlled, the interaction of mice and their 333 microbiome may differ from the interaction of humans and their microbiome. 334 Additionally, mice can be expensive to maintain and they have limited genetic Our study demonstrates a scalable approach to study host-gut microbiome 381 interactions that depicts the in vivo relationship. This technique allowed us to 382 start deciphering the impact of the microbiome on host cells and will help to 383 determine how the microbiome may lead to disease through its influence on host 384 cell gene regulation. We also highlight the importance of gene-by-microbiome 385 interactions and suggest that it is not simply the genetics of an individual but the 386 interplay between genetics and microbiome that will influence health and 387 disease. Future studies using this approach with multiple individuals and 388 microbiomes will identify key host factors and microbial communities that jointly 389 influence human disease. Gene ontology analysis 491 We utilized GeneTrail (91) to find enrichment of gene ontology terms. We 502 We downloaded the GWAS catalog (62)(version 1.0.1) on January 5th, 2016.
Enrichment of DE genes among genome-wide association studies

503
To identify the overlap between DE genes in our dataset and those associated 504 with a GWAS trait, we intersected genes that contain transcripts that change 505 significantly and in the same direction in all 3 treatments with the reported genes 506 from the GWAS catalog. We report enrichment with specific categories from the 507 GWAS catalog: "Obesity-related traits", "Inflammatory bowel disease", "Ulcerative 508 colitis", "Colorectal cancer", "Type 2 diabetes", and "Crohn's disease". We used a 509 Fisher's exact test on a 2x2 contingency table using 2 groups: genes that contain 510 transcripts that are DE, in the same direction, in the 3 treatments ("ALL") and 511 other genes that are expressed in each sample ("NOT"). We then split these 512 groups into 2: genes that are associated with the select disease ("TRAIT") and 513 genes that are associated with any other trait in the GWAS catalog ("OTHER 514 GWAS"). Values are shown in Table S4 . 535 To identify conditional allele-specific expression (cASE) we transformed 536 QuASAR β parameters to differential Z-scores (Z Δ ) using the following formula:
Analysis of cASE
where β and se represent the estimates for the ASE parameter and its standard 539 error for either the treatment (T) or control (C) samples. 540 The Z Δ scores were then normalized by the standard deviation across Z Δ 541 scores corresponding to control versus control (controls at 4 and 6 hours).
542
Finally p-values (p Δ ) were calculated from the Z Δ scores as p Δ = 2 X pnorm(-|z|). 543 Under the null, Z Δ are asymptotically normally distributed. To further correct for 544 this small deviation we used the control versus control p-values to empirically 545 estimate the FDR. The list of significant cASE SNPs (empirical FDR < 12%) is in 546   Table S7 . B) The Venn diagram depicts the number of genes that contain any transcript differentially expressed under the various treatment conditions. The overlap numbers require that the same gene is DE in the different samples. Figure 3 : Functional enrichment of differentially expressed genes. A) GO enrichment was assessed using GeneTrail (87) for any gene differentially expressed in any of the 3 treatments (6,684 genes). Enrichments for the top 10 categories that were over-represented are indicated with a black bar (details in methods). GO enrichment was performed for genes differentially expressed in each of the 3 treatments separately and if these categories were significantly overrepresented, the enrichment in that category is shown by a closed circle (Low-4 is blue, High-4 is red, Low-6 is green). The closed circles are weighted based on the -log 10 (Benjamini-Hochberg adjusted p-value). C) Fold enrichment of DE genes (y-axis) among genes associated in GWAS for a given disease at progressively stringent p-value thresholds (x-axis). For each GWAS and P-value cutoff, we identified the overlap between the genes significantly associated with the disease at that cutoff and DE genes in our study, and calculated a fold enrichment (plotted along the y-axis), defined as the ratio of observed/expected overlap between the two gene sets. Colored lines indicate an enrichment significant at p < 0.05 (using a Fisher's exact test), with the point of maximum enrichment indicated by a circle. The GWAS disease name is listed next to the line for diseases with a fold enrichment > 30 or x-axis position of maximum enrichment > 10. 
